Dave Ricks, CEO of Eli Lilly | The All-In Interview
- Oct 8, 2024
- 1:04:57
- Full Episode
(0:00) Friedberg welcomes Eli Lilly CEO Dave Ricks (2:06) The obesity problem: a global chronic health epidemic (13:07) The history of discovering GLP-1s (20:38) Impact of GLP-1s on different human functions (27:09) Understanding the commercial aspect of drug discovery, pricing for GLP-1 drugs (33:11) Responding to criticism and research of GLP-1 dependency (40:04) Stock performance, dealing with political pressure related to successful drugs (47:19) Eli Lilly's portfolio of drugs outside of GLP-1s, what science Dave is excited about (56:09) Scaling and impacting culture at a 100+ year-old company
Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg
Follow on X: https://x.com/theallinpod
Follow on Instagram: https://www.instagram.com/theallinpod
Follow on TikTok: https://www.tiktok.com/@theallinpod
Follow on LinkedIn: https://www.linkedin.com/company/allinpod
Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg
Intro Video Credit: https://x.com/TheZachEffect
Referenced in the show: https://www.google.com/finance/quote/LLY:NYSE https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/Estat-adults-fig.png https://www.pbs.org/newshour/politics/fda-approves-new-version-of-diabetes-drug-mounjaro-to-be-sold-for-weight-loss https://www.cnn.com/2024/01/08/health/weight-loss-drug-insurance-denials/index.html https://i.insider.com/638f471e57aefa0018eb9a3d?width=800&format=jpeg&auto=webp https://x.com/EconomyApp
Brief Summary
Dave Ricks discusses Eli Lilly's growth, GLP-1 drugs, and the obesity epidemic's health implications.
Key points
- The Impact of Diet. The American diet has shifted dramatically, leading to increased obesity rates.
- Insulin's Evolution. Eli Lilly was the first American company to produce insulin, revolutionizing diabetes treatment.
- GLP-1 Discovery. GLP-1, a hormone that regulates insulin, was discovered to have significant effects.
- Engineering Hormones for Health. Discover how engineered hormones like GLP-1 are changing the landscape of obesity treatment.
- The Cost of Clinical Trials. The financial stakes of clinical trials for obesity drugs are staggering, reaching billions.
- The Challenge of Obesity Treatment. Understanding the complexities of obesity treatment and the need for long-term solutions.
Episode highlights
- The Impact of DietThe American diet has shifted dramatically, leading to increased obesity rates.“The average daily calorie consumed by Americans has driven up significantly.”2:55Oct 8, 2024
- Insulin's EvolutionEli Lilly was the first American company to produce insulin, revolutionizing diabetes treatment.“We were the first company period to produce insulin.”10:20Oct 8, 2024
- GLP-1 DiscoveryGLP-1, a hormone that regulates insulin, was discovered to have significant effects.“GLP-1 stimulates insulin production and secretion.”13:26Oct 8, 2024
- Engineering Hormones for HealthDiscover how engineered hormones like GLP-1 are changing the landscape of obesity treatment.“We could use GLP-1s not just for obesity and diabetes but for other health indications.”23:06Oct 8, 2024
- The Cost of Clinical TrialsThe financial stakes of clinical trials for obesity drugs are staggering, reaching billions.“That's 10 to 20 billion dollars you're spending on clinical trials.”25:39Oct 8, 2024
- The Challenge of Obesity TreatmentUnderstanding the complexities of obesity treatment and the need for long-term solutions.“Losing weight as an adult is really difficult.”30:18Oct 8, 2024
- The Future of Weight Loss DrugsNew oral medications may revolutionize weight loss treatment, making it more accessible.“It's an oral GLP-1 in our hands, it's about as good as high-dose semaglutide.”36:45Oct 8, 2024
- Eli Lilly's Revenue SurgeEli Lilly reports $11 billion in revenue, raising questions about profit margins and ethics.“You're making an 81% gross margin selling these products to sick people.”41:04Oct 8, 2024
